PerkinElmer
check quantity

IL-8 (human) AlphaLISA Biotin-Free Detection Kit, 500 Assay Points

The AlphaLISA Human IL8 Biotin-Free Detection Kit is designed for the quantitative detection of human IL-8 in serum, cell culture medium, and other samples types using a homogeneous (no wash steps, no separation steps) assay. The biotin-free kit uses anti-DIG (anti-Digoxin) Donor beads instead of streptavidin Donor beads, which makes the kit compatible with high-biotin culture media and other sample types that contain high levels biotin (including brain/liver tissue extracts, milk and eggs).

For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).

Part Number
Unit Size
List Price
Your Price
Quantity
AL328HV
100 assay points
828.00 USD
 
more
AL328C
500 assay points
1811.00 USD
 
more
AL328F
5,000 assay points
12000.00 USD
 
more
Buy Now

Please enter valid quantity

Please log in to add favorites.

NULL OR EMPTY CART

Overview

Formats:

  • Our HV (100 assay point) kits allow you to run 100 wells in 96-well format, using a 100 µL reaction volume (10 µL of sample).
  • Our 500 assay point kit allows you to run 500 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample).
  • Our 5,000 assay point kit allows you to run 5,000 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample).

Features and Benefits:

  • No-wash steps, no separation steps
  • Compatible with high biotin samples, including RPMI and high-biotin tissue extracts
  • ELISA alternative technology
  • Sensitive detection
  • Broad sample compatibility
  • Results in less than 3 hours

Interleukin 8 (IL8 or CXCL8), a member of the ELR+ CXC chemokine family, is an 8.4 kDa polypeptide that forms homodimers in vivo. IL8 is secreted by several types of cells: fibroblasts, monocytes, macrophages and endothelial cells, among many others, in response to inflammatory stimuli. It is a chemoattractant and activator for neutrophils, directing them from periferal blood to the site of inflammation. It is also a potent angiogenic factor promoting endothelial and epithelial migration and proliferation in several cancers, and is associated with metastasis. It signals through two specific G protein-coupled receptors, CXCR1 and CXCR2, sharing ~77% identity.

AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA biotin-free assay, a DIG-labeled anti-analyte antibody binds to the anti-DIG-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.

Specifications

Assay Target IL8
Assay Target Class Cytokine
Automation Compatible Yes
Detection Method Alpha
Experimental Type In vitro
Product Brand Name AlphaLISA
Shipping Condition Blue Ice
Therapeutic Area Inflammation
Unit Size 500 assay points
Resources, Events & More
  • All

Application Brief

Eight Limitations of ELISA and How to Overcome Them Using Alternative Technologies

The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.

Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.

PDF 1 MB

Application Note

Effects of 5FU and Sorafenib on Proliferation and Biomarker Expression in a Colorectal Cancer Model Using AlphaLISA and EnSight Solutions

A variety of chemotherapeutic drugs with different modes of action have been developed and tested as potential therapies for colorectal cancer. Characterizing the effects of potential drugs with different modes of action is a key part of the process.

In this application note you will learn:

  • How to rapidly measure multiple biomarkers in both cell culture supernatant and lysates from the same wells of a microplate to examine complex protein expression profiles from a colorectal cancer cellular model
  • Benefits of using AlphaLISA® technology for characterizing the effects of potential drugs with different modes of action on a cell culture model of human colorectal cancer
  • How to measure the effects of drug treatments, such as 5FU and Sorafenib, on cellular proliferation by automated well-imaging and cell counting using the EnSight® multimode plate reader
  • Examples of the data and analysis you can generate for such biomarker and proliferation assays

PDF 3 MB

Brochure